17-alpha-Hydroxyprogesterone
Bevacizumab may increase the cardiotoxic activities of Hydroxyprogesterone caproate.
3,3'-Diindolylmethane
Bevacizumab may increase the cardiotoxic activities of 3,3'-diindolylmethane.
3-Iodobenzylguanidine
Bevacizumab may increase the cardiotoxic activities of Iobenguane.
Advertisement
4-Phenylbutyric Acid
Bevacizumab may increase the cardiotoxic activities of Phenylbutyric acid.
Abiraterone
Bevacizumab may increase the cardiotoxic activities of Abiraterone.
Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Bevacizumab.
Advertisement
Aclarubicin
Bevacizumab may increase the cardiotoxic activities of Aclarubicin.
Ado-Trastuzumab Emtansine
Bevacizumab may increase the cardiotoxic activities of Trastuzumab emtansine.
Afatinib
Bevacizumab may increase the cardiotoxic activities of Afatinib.
Advertisement
Aflibercept
Bevacizumab may increase the cardiotoxic activities of Aflibercept.
Alatrofloxacin
Bevacizumab may increase the cardiotoxic activities of Alatrofloxacin.
Albendazole
Bevacizumab may increase the cardiotoxic activities of Albendazole.
Aldesleukin
Bevacizumab may increase the cardiotoxic activities of Aldesleukin.
Alectinib
Bevacizumab may increase the cardiotoxic activities of Alectinib.
Alemtuzumab
Bevacizumab may increase the cardiotoxic activities of Alemtuzumab.
Alitretinoin
Bevacizumab may increase the cardiotoxic activities of Alitretinoin.
All-Trans-Retinol
Bevacizumab may increase the cardiotoxic activities of Vitamin A.
Altretamine
Bevacizumab may increase the cardiotoxic activities of Altretamine.
Aminoglutethimide
Bevacizumab may increase the cardiotoxic activities of Aminoglutethimide.
Aminolevulinic Acid
Bevacizumab may increase the cardiotoxic activities of Aminolevulinic acid.
Amonafide
Bevacizumab may increase the cardiotoxic activities of Amonafide.
Amsacrine
Bevacizumab may increase the cardiotoxic activities of Amsacrine.
Anagrelide
Bevacizumab may increase the cardiotoxic activities of Anagrelide.
Anastrozole
Bevacizumab may increase the cardiotoxic activities of Anastrozole.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Bevacizumab.
Anthrax immune globulin, human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bevacizumab.
Arsenic Trioxide
Bevacizumab may increase the cardiotoxic activities of Arsenic trioxide.
ASPARAGINASE
Bevacizumab may increase the cardiotoxic activities of Asparaginase Escherichia coli.
asparaginase Erwinia chrysanthemi
Bevacizumab may increase the cardiotoxic activities of Asparaginase Erwinia chrysanthemi.
Atezolizumab
Bevacizumab may increase the cardiotoxic activities of Atezolizumab.
Avelumab
Bevacizumab may increase the cardiotoxic activities of Avelumab.
Axitinib
Bevacizumab may increase the cardiotoxic activities of Axitinib.
Azacitidine
Bevacizumab may increase the cardiotoxic activities of Azacitidine.
Azathioprine
Bevacizumab may increase the cardiotoxic activities of Azathioprine.
Azelaic Acid
Bevacizumab may increase the cardiotoxic activities of Azelaic Acid.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Bevacizumab.
BCG, Live, Connaught Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Bevacizumab.
BCG, Live, Tice Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Bevacizumab.
Belimumab
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Belimumab.
Belinostat
Bevacizumab may increase the cardiotoxic activities of Belinostat.
Bendamustine
Bevacizumab may increase the cardiotoxic activities of Bendamustine.
Besifloxacin
Bevacizumab may increase the cardiotoxic activities of Besifloxacin.
Bexarotene
Bevacizumab may increase the cardiotoxic activities of Bexarotene.
Bicalutamide
Bevacizumab may increase the cardiotoxic activities of Bicalutamide.
Binetrakin
Bevacizumab may increase the cardiotoxic activities of Binetrakin.
Bleomycin
Bevacizumab may increase the cardiotoxic activities of Bleomycin.
Blinatumomab
Bevacizumab may increase the cardiotoxic activities of Blinatumomab.
Bortezomib
Bevacizumab may increase the cardiotoxic activities of Bortezomib.
Bosutinib
Bevacizumab may increase the cardiotoxic activities of Bosutinib.
Bosutinib monohydrate
Bevacizumab may increase the cardiotoxic activities of Bosutinib.
Brentuximab Vedotin
Bevacizumab may increase the cardiotoxic activities of Brentuximab vedotin.
Buserelin
Bevacizumab may increase the cardiotoxic activities of Buserelin.
Busulfan
Bevacizumab may increase the cardiotoxic activities of Busulfan.
Cabazitaxel
Bevacizumab may increase the cardiotoxic activities of Cabazitaxel.
Cabergoline
Bevacizumab may increase the cardiotoxic activities of Cabergoline.
Cabozantinib
Bevacizumab may increase the cardiotoxic activities of Cabozantinib.
Calcipotriene
Bevacizumab may increase the cardiotoxic activities of Calcipotriol.
Capecitabine
Bevacizumab may increase the cardiotoxic activities of Capecitabine.
Carboplatin
Bevacizumab may increase the cardiotoxic activities of Carboplatin.
Carfilzomib
Bevacizumab may increase the cardiotoxic activities of Carfilzomib.
Carmustine
Bevacizumab may increase the cardiotoxic activities of Carmustine.
Celecoxib
Bevacizumab may increase the cardiotoxic activities of Celecoxib.
Ceritinib
Bevacizumab may increase the cardiotoxic activities of Ceritinib.
Cetuximab
Bevacizumab may increase the cardiotoxic activities of Cetuximab.
Chlorambucil
Bevacizumab may increase the cardiotoxic activities of Chlorambucil.
Chlorotrianisene
Bevacizumab may increase the cardiotoxic activities of Chlorotrianisene.
Cinoxacin
Bevacizumab may increase the cardiotoxic activities of Cinoxacin.
Ciprofloxacin
Bevacizumab may increase the cardiotoxic activities of Ciprofloxacin.
Cisplatin
Bevacizumab may increase the cardiotoxic activities of Cisplatin.
Cladribine
Bevacizumab may increase the cardiotoxic activities of Cladribine.
Clofarabine
Bevacizumab may increase the cardiotoxic activities of Clofarabine.
Clozapine
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Clozapine.
Cobimetinib
Bevacizumab may increase the cardiotoxic activities of Cobimetinib.
Colchicine
Bevacizumab may increase the cardiotoxic activities of Colchicine.
Cordycepin
Bevacizumab may increase the cardiotoxic activities of Cordycepin.
Crizotinib
Bevacizumab may increase the cardiotoxic activities of Crizotinib.
Curcumin
Bevacizumab may increase the cardiotoxic activities of Curcumin.
Cyclophosphamide
Bevacizumab may increase the cardiotoxic activities of Cyclophosphamide.
Cyclophosphamide Anhydrous
Bevacizumab may increase the cardiotoxic activities of Cyclophosphamide.
Cyproterone Acetate
Bevacizumab may increase the cardiotoxic activities of Cyproterone acetate.
Cytarabine
Bevacizumab may increase the cardiotoxic activities of Cytarabine.
Dabrafenib
Bevacizumab may increase the cardiotoxic activities of Dabrafenib.
Dacarbazine
Bevacizumab may increase the cardiotoxic activities of Dacarbazine.
Dactinomycin
Bevacizumab may increase the cardiotoxic activities of Dactinomycin.
Daratumumab
Bevacizumab may increase the cardiotoxic activities of Daratumumab.
Dasatinib
Bevacizumab may increase the cardiotoxic activities of Dasatinib.
Dasatinib Anhydrous
Bevacizumab may increase the cardiotoxic activities of Dasatinib.
Daunorubicin
Bevacizumab may increase the cardiotoxic activities of Daunorubicin.
Decitabine
Bevacizumab may increase the cardiotoxic activities of Decitabine.
Degarelix
Bevacizumab may increase the cardiotoxic activities of Degarelix.
Denileukin Diftitox
Bevacizumab may increase the cardiotoxic activities of Denileukin diftitox.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Bevacizumab.
Dexamethasone
Bevacizumab may increase the cardiotoxic activities of Dexamethasone.
Dexrazoxane
Bevacizumab may increase the cardiotoxic activities of Dexrazoxane.
Dienogest
Bevacizumab may increase the cardiotoxic activities of Dienogest.
Diethylstilbestrol
Bevacizumab may increase the cardiotoxic activities of Diethylstilbestrol.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Bevacizumab.
Digoxin
Digoxin may decrease the cardiotoxic activities of Bevacizumab.
Dinutuximab
Bevacizumab may increase the cardiotoxic activities of Dinutuximab.
Dipyrone
The risk or severity of myelosuppression can be increased when Metamizole is combined with Bevacizumab.
Docetaxel
Bevacizumab may increase the cardiotoxic activities of Docetaxel.
DOCETAXEL ANHYDROUS
Bevacizumab may increase the cardiotoxic activities of Docetaxel.
Doxorubicin
Bevacizumab may increase the cardiotoxic activities of Doxorubicin.
Doxorubicin Hydrochloride
Bevacizumab may increase the cardiotoxic activities of Doxorubicin.
Durvalumab
Bevacizumab may increase the cardiotoxic activities of Durvalumab.
Edrecolomab
Bevacizumab may increase the cardiotoxic activities of Edrecolomab.
Eflornithine
Bevacizumab may increase the cardiotoxic activities of Eflornithine.
Elotuzumab
Bevacizumab may increase the cardiotoxic activities of Elotuzumab.
Enoxacin
Bevacizumab may increase the cardiotoxic activities of Enoxacin.
Enzalutamide
Bevacizumab may increase the cardiotoxic activities of Enzalutamide.
Epigallocatechin Gallate
Bevacizumab may increase the cardiotoxic activities of Epigallocatechin Gallate.
Epirubicin
Bevacizumab may increase the cardiotoxic activities of Epirubicin.
Eribulin
Bevacizumab may increase the cardiotoxic activities of Eribulin.
Erlotinib
Bevacizumab may increase the cardiotoxic activities of Erlotinib.
Erwinia asparaginase
Bevacizumab may increase the cardiotoxic activities of Asparaginase Erwinia chrysanthemi.
Estramustine
Bevacizumab may increase the cardiotoxic activities of Estramustine.
Ethiodized Oil
Bevacizumab may increase the cardiotoxic activities of Ethiodized oil.
Etoposide
Bevacizumab may increase the cardiotoxic activities of Etoposide.
Everolimus
Bevacizumab may increase the cardiotoxic activities of Everolimus.
Exemestane
Bevacizumab may increase the cardiotoxic activities of Exemestane.
Fleroxacin
Bevacizumab may increase the cardiotoxic activities of Fleroxacin.
Floxuridine
Bevacizumab may increase the cardiotoxic activities of Floxuridine.
Fludarabine
Bevacizumab may increase the cardiotoxic activities of Fludarabine.
Flumequine
Bevacizumab may increase the cardiotoxic activities of Flumequine.
Fluorouracil
Bevacizumab may increase the cardiotoxic activities of Fluorouracil.
Flutamide
Bevacizumab may increase the cardiotoxic activities of Flutamide.
Formestane
Bevacizumab may increase the cardiotoxic activities of Formestane.
Fulvestrant
Bevacizumab may increase the cardiotoxic activities of Fulvestrant.
Fumagillin
Bevacizumab may increase the cardiotoxic activities of Fumagillin.
Gallium Nitrate
Bevacizumab may increase the cardiotoxic activities of Gallium nitrate.
Gatifloxacin
Bevacizumab may increase the cardiotoxic activities of Gatifloxacin.
Gatifloxacin Anhydrous
Bevacizumab may increase the cardiotoxic activities of Gatifloxacin.
Gefitinib
Bevacizumab may increase the cardiotoxic activities of Gefitinib.
Gemcitabine
Bevacizumab may increase the cardiotoxic activities of Gemcitabine.
Gemifloxacin
Bevacizumab may increase the cardiotoxic activities of Gemifloxacin.
Gemifloxacin Mesylate
Bevacizumab may increase the cardiotoxic activities of Gemifloxacin.
Gemtuzumab ozogamicin
Bevacizumab may increase the cardiotoxic activities of Gemtuzumab ozogamicin.
Genistein
Bevacizumab may increase the cardiotoxic activities of Genistein.
Goserelin
Bevacizumab may increase the cardiotoxic activities of Goserelin.
Grepafloxacin
Bevacizumab may increase the cardiotoxic activities of Grepafloxacin.
Hepatitis A Vaccine, Inactivated
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Bevacizumab.
Hepatitis B Surface Antigen Vaccine
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Bevacizumab.
hydroxyprogesterone caproate (USP)
Bevacizumab may increase the cardiotoxic activities of Hydroxyprogesterone caproate.
Hydroxyurea
Bevacizumab may increase the cardiotoxic activities of Hydroxyurea.
Hypericin
Bevacizumab may increase the cardiotoxic activities of Hypericin.
Ibrutinib
Bevacizumab may increase the cardiotoxic activities of Ibrutinib.
Idarubicin
Bevacizumab may increase the cardiotoxic activities of Idarubicin.
Idelalisib
Bevacizumab may increase the cardiotoxic activities of Idelalisib.
Ifosfamide
Bevacizumab may increase the cardiotoxic activities of Ifosfamide.
Imatinib
Bevacizumab may increase the cardiotoxic activities of Imatinib.
Imiquimod
Bevacizumab may increase the cardiotoxic activities of Imiquimod.
Inotuzumab Ozogamicin
Bevacizumab may increase the cardiotoxic activities of Inotuzumab ozogamicin.
Interferon Alfa-2b
Bevacizumab may increase the cardiotoxic activities of Interferon Alfa-2b, Recombinant.
Interferon beta-1a
Bevacizumab may increase the cardiotoxic activities of Interferon beta-1a.
Interleukin-4
Bevacizumab may increase the cardiotoxic activities of Binetrakin.
Ipilimumab
Bevacizumab may increase the cardiotoxic activities of Ipilimumab.
Irinotecan
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Irinotecan.
Isosorbide
Bevacizumab may increase the cardiotoxic activities of Isosorbide.
Ixabepilone
Bevacizumab may increase the cardiotoxic activities of Ixabepilone.
Ixazomib
Bevacizumab may increase the cardiotoxic activities of Ixazomib.
Lanreotide
Bevacizumab may increase the cardiotoxic activities of Lanreotide.
Lapatinib
Bevacizumab may increase the cardiotoxic activities of Lapatinib.
Leflunomide
Bevacizumab may increase the cardiotoxic activities of Leflunomide.
Lenalidomide
Bevacizumab may increase the cardiotoxic activities of Lenalidomide.
Lenvatinib
Bevacizumab may increase the cardiotoxic activities of Lenvatinib.
Lenvatinib Mesylate
Bevacizumab may increase the cardiotoxic activities of Lenvatinib.
Letrozole
Bevacizumab may increase the cardiotoxic activities of Letrozole.
Leuprolide
Bevacizumab may increase the cardiotoxic activities of Leuprolide.
Levofloxacin
Bevacizumab may increase the cardiotoxic activities of Levofloxacin.
Levofloxacin Anhydrous
Bevacizumab may increase the cardiotoxic activities of Levofloxacin.
Lipegfilgrastim
Bevacizumab may increase the myelosuppressive activities of Lipegfilgrastim.
Lomefloxacin
Bevacizumab may increase the cardiotoxic activities of Lomefloxacin.
Lomustine
Bevacizumab may increase the cardiotoxic activities of Lomustine.
Lycopene
Bevacizumab may increase the cardiotoxic activities of Lycopene.
Masoprocol
Bevacizumab may increase the cardiotoxic activities of Masoprocol.
Mebendazole
Bevacizumab may increase the cardiotoxic activities of Mebendazole.
Mechlorethamine
Bevacizumab may increase the cardiotoxic activities of Mechlorethamine.
Medrogestone
Bevacizumab may increase the cardiotoxic activities of Medrogestone.
Medroxyprogesterone Acetate
Bevacizumab may increase the cardiotoxic activities of Medroxyprogesterone acetate.
Megestrol Acetate
Bevacizumab may increase the cardiotoxic activities of Megestrol acetate.
Melphalan
Bevacizumab may increase the cardiotoxic activities of Melphalan.
Mequinol
Bevacizumab may increase the cardiotoxic activities of Mequinol.
Mercaptopurine
Bevacizumab may increase the cardiotoxic activities of Mercaptopurine.
MERCAPTOPURINE ANHYDROUS
Bevacizumab may increase the cardiotoxic activities of Mercaptopurine.
Methotrexate
Bevacizumab may increase the cardiotoxic activities of Methotrexate.
Methyl 5-Aminolevulinate
Bevacizumab may increase the cardiotoxic activities of Methyl aminolevulinate.
Methylprednisolone
Bevacizumab may increase the cardiotoxic activities of Methylprednisolone.
Methyltestosterone
Bevacizumab may increase the cardiotoxic activities of Methyltestosterone.
Midostaurin
Bevacizumab may increase the cardiotoxic activities of Midostaurin.
Miltefosine
Bevacizumab may increase the cardiotoxic activities of Miltefosine.
Mitomycin
Bevacizumab may increase the cardiotoxic activities of Mitomycin.
Mitotane
Bevacizumab may increase the cardiotoxic activities of Mitotane.
Mitoxantrone
Bevacizumab may increase the cardiotoxic activities of Mitoxantrone.
Molgramostim
Bevacizumab may increase the cardiotoxic activities of Molgramostim.
Moxifloxacin
Bevacizumab may increase the cardiotoxic activities of Moxifloxacin.
MYCOPHENOLATE
Bevacizumab may increase the cardiotoxic activities of Mycophenolic acid.
Mycophenolate Mofetil
Bevacizumab may increase the cardiotoxic activities of Mycophenolate mofetil.
Mycophenolic Acid
Bevacizumab may increase the cardiotoxic activities of Mycophenolic acid.
Nalidixic Acid
Bevacizumab may increase the cardiotoxic activities of Nalidixic Acid.
Necitumumab
Bevacizumab may increase the cardiotoxic activities of Necitumumab.
Nelarabine
Bevacizumab may increase the cardiotoxic activities of Nelarabine.
Nilotinib
Bevacizumab may increase the cardiotoxic activities of Nilotinib.
Nilutamide
Bevacizumab may increase the cardiotoxic activities of Nilutamide.
Nintedanib
Bevacizumab may increase the cardiotoxic activities of Nintedanib.
Niraparib
Bevacizumab may increase the cardiotoxic activities of Niraparib.
Nivolumab
Bevacizumab may increase the cardiotoxic activities of Nivolumab.
Norfloxacin
Bevacizumab may increase the cardiotoxic activities of Norfloxacin.
Obinutuzumab
Bevacizumab may increase the cardiotoxic activities of Obinutuzumab.
Octreotide
Bevacizumab may increase the cardiotoxic activities of Octreotide.
Ofatumumab
Bevacizumab may increase the cardiotoxic activities of Ofatumumab.
Ofloxacin
Bevacizumab may increase the cardiotoxic activities of Ofloxacin.
Olaparib
Bevacizumab may increase the cardiotoxic activities of Olaparib.
Olaratumab
Bevacizumab may increase the cardiotoxic activities of Olaratumab.
Omacetaxine Mepesuccinate
Bevacizumab may increase the cardiotoxic activities of Omacetaxine mepesuccinate.
Oprelvekin
Bevacizumab may increase the cardiotoxic activities of Oprelvekin.
Osimertinib
Bevacizumab may increase the cardiotoxic activities of Osimertinib.
Ouabain
Ouabain may decrease the cardiotoxic activities of Bevacizumab.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Bevacizumab.
Oxaliplatin
Bevacizumab may increase the cardiotoxic activities of Oxaliplatin.
Paclitaxel
Bevacizumab may increase the cardiotoxic activities of Paclitaxel.
Palbociclib
Bevacizumab may increase the cardiotoxic activities of Palbociclib.
Pamidronate
Bevacizumab may increase the cardiotoxic activities of Pamidronate.
Pamidronic Acid
Bevacizumab may increase the cardiotoxic activities of Pamidronate.
Panitumumab
Bevacizumab may increase the cardiotoxic activities of Panitumumab.
Panobinostat
Bevacizumab may increase the cardiotoxic activities of Panobinostat.
Pazopanib
Bevacizumab may increase the cardiotoxic activities of Pazopanib.
Pefloxacin
Bevacizumab may increase the cardiotoxic activities of Pefloxacin.
Pegaspargase
Bevacizumab may increase the cardiotoxic activities of Pegaspargase.
Pembrolizumab
Bevacizumab may increase the cardiotoxic activities of Pembrolizumab.
Pemetrexed
Bevacizumab may increase the cardiotoxic activities of Pemetrexed.
Pentostatin
Bevacizumab may increase the cardiotoxic activities of Pentostatin.
Pertuzumab
Bevacizumab may increase the cardiotoxic activities of Pertuzumab.
Phenylacetic Acid
Bevacizumab may increase the cardiotoxic activities of Phenylacetic acid.
Phenylbutyrate
Bevacizumab may increase the cardiotoxic activities of Phenylbutyric acid.
Pipobroman
Bevacizumab may increase the cardiotoxic activities of Pipobroman.
Pirarubicin
Bevacizumab may increase the cardiotoxic activities of Pirarubicin.
Pirfenidone
Bevacizumab may increase the cardiotoxic activities of Pirfenidone.
Plicamycin
Bevacizumab may increase the cardiotoxic activities of Plicamycin.
Podofilox
Bevacizumab may increase the cardiotoxic activities of Podofilox.
Podophyllin
Bevacizumab may increase the cardiotoxic activities of Podophyllin.
Pomalidomide
Bevacizumab may increase the cardiotoxic activities of Pomalidomide.
Ponatinib
Bevacizumab may increase the cardiotoxic activities of Ponatinib.
Porfimer Sodium
Bevacizumab may increase the cardiotoxic activities of Porfimer sodium.
Pralatrexate
Bevacizumab may increase the cardiotoxic activities of Pralatrexate.
Prednimustine
Bevacizumab may increase the cardiotoxic activities of Prednimustine.
Prednisolone
Bevacizumab may increase the cardiotoxic activities of Prednisolone.
Prednisone
Bevacizumab may increase the cardiotoxic activities of Prednisone.
Procarbazine
Bevacizumab may increase the cardiotoxic activities of Procarbazine.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Bevacizumab.
Quinacrine
Bevacizumab may increase the cardiotoxic activities of Quinacrine.
Rabies Immune Globulin, Human
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Bevacizumab.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Bevacizumab.
RADIUM CHLORIDE RA-223
Bevacizumab may increase the cardiotoxic activities of Radium Ra 223 Dichloride.
Raltitrexed
Bevacizumab may increase the cardiotoxic activities of Raltitrexed.
Ramucirumab
Bevacizumab may increase the cardiotoxic activities of Ramucirumab.
Ranibizumab
Bevacizumab may increase the cardiotoxic activities of Ranibizumab.
Regorafenib
Bevacizumab may increase the cardiotoxic activities of Regorafenib.
Resveratrol
Bevacizumab may increase the cardiotoxic activities of Resveratrol.
Ribociclib
Bevacizumab may increase the cardiotoxic activities of Ribociclib.
Rituximab
Bevacizumab may increase the cardiotoxic activities of Rituximab.
Romidepsin
Bevacizumab may increase the cardiotoxic activities of Romidepsin.
ROTAVIRUS VACCINE, LIVE
The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Bevacizumab.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Bevacizumab.
Rucaparib
Bevacizumab may increase the cardiotoxic activities of Rucaparib.
Ruxolitinib
Bevacizumab may increase the cardiotoxic activities of Ruxolitinib.
Salmonella enterica subsp. enterica serovar typhi
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Bevacizumab.
Satraplatin
Bevacizumab may increase the cardiotoxic activities of Satraplatin.
Siltuximab
Bevacizumab may increase the cardiotoxic activities of Siltuximab.
Sirolimus
Bevacizumab may increase the cardiotoxic activities of Sirolimus.
Sonidegib
Bevacizumab may increase the cardiotoxic activities of Sonidegib.
Sorafenib
The risk or severity of adverse effects can be increased when Bevacizumab is combined with Sorafenib.
Sparfloxacin
Bevacizumab may increase the cardiotoxic activities of Sparfloxacin.
Streptozocin
Bevacizumab may increase the cardiotoxic activities of Streptozocin.
Sulindac
Bevacizumab may increase the cardiotoxic activities of Sulindac.
Sunitinib
The risk or severity of adverse effects can be increased when Sunitinib is combined with Bevacizumab.
Suramin
Bevacizumab may increase the cardiotoxic activities of Suramin.
Tamoxifen
Bevacizumab may increase the cardiotoxic activities of Tamoxifen.
Tegafur
Bevacizumab may increase the cardiotoxic activities of Tegafur.
Temafloxacin
Bevacizumab may increase the cardiotoxic activities of Temafloxacin.
Temoporfin
Bevacizumab may increase the cardiotoxic activities of Temoporfin.
Temozolomide
Bevacizumab may increase the cardiotoxic activities of Temozolomide.
Temsirolimus
Bevacizumab may increase the cardiotoxic activities of Temsirolimus.
Teniposide
Bevacizumab may increase the cardiotoxic activities of Teniposide.
Testolactone
Bevacizumab may increase the cardiotoxic activities of Testolactone.
Tetanus Toxoid Vaccine, Inactivated
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bevacizumab.
Thalidomide
Bevacizumab may increase the cardiotoxic activities of Thalidomide.
Thioguanine
Bevacizumab may increase the cardiotoxic activities of Tioguanine.
Thioguanine Anhydrous
Bevacizumab may increase the cardiotoxic activities of Tioguanine.
Thiotepa
Bevacizumab may increase the cardiotoxic activities of Thiotepa.
Thymalfasin
Bevacizumab may increase the cardiotoxic activities of Thymalfasin.
Tibolone
Bevacizumab may increase the cardiotoxic activities of Tibolone.
Topotecan
Bevacizumab may increase the cardiotoxic activities of Topotecan.
Toremifene
Bevacizumab may increase the cardiotoxic activities of Toremifene.
Tositumomab
Bevacizumab may increase the cardiotoxic activities of Tositumomab.
Trabectedin
Bevacizumab may increase the cardiotoxic activities of Trabectedin.
Trametinib
Bevacizumab may increase the cardiotoxic activities of Trametinib.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Bevacizumab.
Treosulfan
Bevacizumab may increase the cardiotoxic activities of Treosulfan.
Tretinoin
Bevacizumab may increase the cardiotoxic activities of Tretinoin.
Trifluridine
Bevacizumab may increase the cardiotoxic activities of Trifluridine.
Trilostane
Bevacizumab may increase the cardiotoxic activities of Trilostane.
Trimetrexate
Bevacizumab may increase the cardiotoxic activities of Trimetrexate.
Triptorelin
Bevacizumab may increase the cardiotoxic activities of Triptorelin.
Trofosfamide
Bevacizumab may increase the cardiotoxic activities of Trofosfamide.
Trovafloxacin
Bevacizumab may increase the cardiotoxic activities of Trovafloxacin.
Typhoid Vaccine Live Ty21a
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Bevacizumab.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Bevacizumab.
Uracil Mustard
Bevacizumab may increase the cardiotoxic activities of Uracil mustard.
Urethane
Bevacizumab may increase the cardiotoxic activities of Ethyl carbamate.
Valrubicin
Bevacizumab may increase the cardiotoxic activities of Valrubicin.
Vandetanib
Bevacizumab may increase the cardiotoxic activities of Vandetanib.
Varicella Virus Vaccine Live (Oka-Merck) strain
The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Bevacizumab.
Vemurafenib
Bevacizumab may increase the cardiotoxic activities of Vemurafenib.
Venetoclax
Bevacizumab may increase the cardiotoxic activities of Venetoclax.
Verteporfin
Bevacizumab may increase the cardiotoxic activities of Verteporfin.
Vinblastine
Bevacizumab may increase the cardiotoxic activities of Vinblastine.
Vincristine
Bevacizumab may increase the cardiotoxic activities of Vincristine.
Vindesine
Bevacizumab may increase the cardiotoxic activities of Vindesine.
Vinorelbine
Bevacizumab may increase the cardiotoxic activities of Vinorelbine.
Vismodegib
Bevacizumab may increase the cardiotoxic activities of Vismodegib.
Vorinostat
Bevacizumab may increase the cardiotoxic activities of Vorinostat.
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Bevacizumab.
Yellow-Fever Virus Vaccine, 17D-204 strain
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Bevacizumab.
Ziv-Aflibercept
Bevacizumab may increase the cardiotoxic activities of Aflibercept.
